• progression-free survival as assessed by independent radiology review [ Time Frame: every 8 weeks after randomization ] [ Designated as safety issue: Yes ]
  

• overall survival [ Time Frame: every 8 weeks for first 2 years then every 3 months thereafter ] [ Designated as safety issue: Yes ]
  
• response rate [ Time Frame: every 8 weeks ] [ Designated as safety issue: No ]
  
• safety [ Time Frame: weekly until treatment is terminated ] [ Designated as safety issue: Yes ]
  
• pharmacokinetics [ Time Frame: weekly during cycle 1 & 2 ] [ Designated as safety issue: No ]
  

This is a multicenter, open-label, randomized, Phase 3 study comparing the combination of Doxil, 30mg/m2, administered as a 90-minute infusion followed by trabectedin, 1.1 mg/m2 3-hour infusion, every 3 weeks with DOXIL, 50 mg/m2 as a 90-minute infusion every 4 weeks, in previously treated patients with advanced ovarian cancer for whom first-line platinum-based chemotherapy regimen has failed. The purpose of this research study is to determine if the combination of trabectedin and DOXIL is better at improving progression free survival over DOXIL alone in patients with relapsed advanced ovarian cancer. Additional comparisons between the two treatment groups include: overall survival, measurement of disease progression, response rate, (how much your tumor shrinks in response to the drug) safety, pharmacokinetics (measuring the amount of drug in your body), quality of life, and optional measurement of circulating tumor cells if present. Patients may receive either a combination of trabectedin and DOXIL (Group A) or DOXIL alone (Group B). If you are in Group A you will receive dexamethasone followed by Trabectedin 1.1 mg/m² as a 3 hour infusion + DOXIL 30 mg/m² every 3 weeks as long as you are responding to treatment. If you are in Group B you will receive DOXIL 50 mg/m2 every 4 weeks as long as you are responding to treatment.